(Q42287613)
Statements
1 reference
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results (English)
1 reference
Jean-Michel Molina
1 reference
David Cooper
1 reference
Richard Elion
1 reference
José Ramón Arribas López
1 reference
Franco Maggiolo
1 reference
Edmund Wilkins
1 reference
Brian Conway
1 reference
Ya-Pei Liu
1 reference
Nicolas Margot
1 reference
Martin Rhee
1 reference
Steven L Chuck
1 reference
Javier Szwarcberg
1 reference
Study 145 Team
1 reference
1 August 2013
1 reference
1 reference
63
1 reference
4
1 reference
494-497
1 reference
Identifiers
1 reference
1 reference